Truist raised the firm’s price target on Amgen (AMGN) to $327 from $325 and keeps a Hold rating on the shares after its inline Q1 results for revenue and a beat on earnings, with a modest FY26 guidance uplift. MariTide remains the topic du jour, with new maintenance and switch studies that could support a smoother path to market, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Closing Bell Movers: Apple higher after stronger than expected guidance
- Amgen raises FY26 adjusted EPS view to $21.70-$23.10 from $21.60-$23.00
- Amgen reports Q1 adjusted EPS $5.15, consensus $4.77
- Amgen sees FY26 CapEx $2.6B; share repurchases not to exceed $3B
- Notable companies reporting after market close